Effect of NEUROAID on Stroke

Assessment of the effect of NEUROAID on patient function after stroke in 60-85 years old patients with ischemic stroke in MCA territory refered to Golestan Hospital, Ahvaz.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138905103663N2

Enrollment

Registered

2010-10-31

Start date

2010-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral ischemic stroke. Cerebral infarction due to thrombosis of cerebral arteries

Interventions

Intervention 1: Neuroaid, oral capsule, 4 capsules 400 milligram TDS for 3 months in intervention group. Intervention 2: Placebo, oral capsule, 4 capsules TDS for 3 months in control group.

Treatment - Drugs

Placebo

Neuroaid, oral capsule, 4 capsules 400 milligram TDS for 3 months in intervention group.

Placebo, oral capsule, 4 capsules TDS for 3 months in control group.

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Having ischemic cerebral infarction confirmed by imaging (CT scan or MRI) in the territory of middle cerebral artery, Admission on hospital during 24 hours after the event, Age older than 60 years old, Subjects or legally acceptable representative (first degree relatives) is willing and able to provide written informed consent, Having the ability to swallow normally and to comply the study schedule of treatment. Exclusion criteria: Having the evidence of intra-cerebral hemorrhage or hemorrhagic conversion on brain imaging, Any other brain pathology other than current ischemic infarction, Previous history of stroke, Signing old stroke in brain imaging, Existence of systemic disease: COPD, severe asthma, CO2 narcosis, renal failure, severe congestive heart failure, uncontrolled hypertension, uremia, cirrhosis, psychosis, dementia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Patient's function. Timepoint: Before intervention and one week and 3 months after intervention. Method of measurement: By means of Barthele-MRS index.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: Every month for three months. Method of measurement: By checklist and assessment by researcher and patient, and monthly visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaied Aidin Sajedin, MD

Jundishapur University of Medical Sciences

dr.sajedy@gmail.com+98 61 1374 3012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026